The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
Inventiva, which is making solid progress with its candidate for the highly challenging non-alcoholic steatohepatitis (NASH) indication, saw its shares shoot up more than 25% to 5.06 euros yesterday, after the French biotech announced a lucrative licensing deal for its drug lanifibranor in China. 23 September 2022
UK-based GSK’s latest deal has defied the long-term trend among big pharma companies to move investment away from the high-risk, low returns antibiotic space. 22 September 2022
As with any big pharma company, Swiss giant Novartis periodically holds events to inform shareholders and other interested parties on its updated strategy and optimism for future drug sales. 22 September 2022
There was positive news from US pharma giant Merck & Co this morning, with respect to patent litigation relating to its blockbuster diabetes drug franchise. 22 September 2022
Shares of US pharma major Eli Lilly edged up 1.4% to $300.68 pre-market today, on the news that its RET kinase inhibitor Retevmo (selpercatinib) had received a second approval in the USA. 22 September 2022
Investors are jittery after the sudden departure of French drugmaker Servier from a collaboration in oncology with San Francisco’s Allogene Therapeutics. 22 September 2022
Shares of US biotech Sesen Bio (Nasdaq: SESN) tumbled nearly 33% to $0.45 by close of trading yesterday, after it revealed a plan to merge with privately-held Carisma Therapeutics. 22 September 2022
USA-based Adamis Pharmaceuticals saw its shares plunge as much as 42% yesterday, after releasing disappoint trial results of its COVID-19 treatment candidate. 22 September 2022
Coeptis Therapeutics has raided the nearby University of Pittsburgh in the latest step towards realizing the company’s aim of disrupting conventional treatment paradigms. 21 September 2022
A drug candidate that Japan’s largest drugmaker Takeda Pharmaceutical pretty much decided to discontinue back in 2015, has now been out-licensed in a deal that could earn the firm nearly $300 million should it prove successful, albeit with a modest upfront payment. 21 September 2022
Drug pricing policy changes in the USA were signed into law as part of the Inflation Reduction Act last month in one of the most impactful acts of the Biden administration so far. 21 September 2022
Aiming to delve further into the use of poly ADP-ribose polymerase inhibitor, German life sciences major Merck KGaA has linked up with a leading Italian oncology discovery organization. 21 September 2022
Shares in US biopharma Spectrum Pharmaceuticals dropped by a massive 37% on Tuesday while those in Swedish biotech Oncopeptides closed 25% lower. 21 September 2022
Nine months after gaining its first approval in the USA, AstraZeneca’s Tezspire (tezepelumab) has now been approved in the European Union (EU). 21 September 2022
More clinical setbacks for the systemic vasodilator treprostinil have forced United Therapeutics to stop a late-stage trial, sending shares down 5% on Tuesday. 21 September 2022
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has issued a final appraisal document (FAD) recommending Brukinsa (zanubrutinib). 21 September 2022
Driven by the launch of longer-acting anti-vascular endothelial growth factor (VEGF) therapies among other pioneering pipeline therapies, the diabetic macular edema market is expected to more than double over the next decade. 21 September 2022